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Abstract
The aim of the study is to compare the efficacy of flecainide, beta-blockers, sotalol, and verapamil in children with frequent 
PVCs, with or without asymptomatic VT. Frequent premature ventricular complexes (PVCs) and asymptomatic ventricular 
tachycardia (VT) in children with structurally normal hearts require anti-arrhythmic drug (AAD) therapy depending on the 
severity of symptoms or ventricular dysfunction; however, data on efficacy in children are scarce. Both symptomatic and 
asymptomatic children (≥ 1 year and < 18 years of age) with a PVC burden of 5% or more, with or without asymptomatic runs 
of VT, who had consecutive Holter recordings, were included in this retrospective multi-center study. The groups of patients 
receiving AAD therapy were compared to an untreated control group. A medication episode was defined as a timeframe 
in which the highest dosage at a fixed level of a single drug was used in a patient. A total of 35 children and 46 medication 
episodes were included, with an overall change in PVC burden on Holter of -4.4 percentage points, compared to -4.2 in the 
control group of 14 patients. The mean reduction in PVC burden was only significant in patients receiving flecainide (− 13.8 
percentage points; N = 10; p = 0.032), compared to the control group and other groups receiving beta-blockers (− 1.7 percent-
age points; N = 18), sotalol (+ 1.0 percentage points; N = 7), or verapamil (− 3.9 percentage points; N = 11). The efficacy of 
anti-arrhythmic drug therapy on frequent PVCs or asymptomatic VTs in children is very limited. Only flecainide appears to 
be effective in lowering the PVC burden.
Keywords Premature ventricular complexes · Ventricular tachycardia · Children · Anti-arrhythmic drugs · Flecainide · 
Metoprolol
Introduction
Frequent premature ventricular contractions (PVCs) and 
asymptomatic ventricular tachycardia (VT) in children with 
structurally normal hearts are uncommon, less than 5% of 
school-aged children will have more than 50 PVCs per 24 h.
[1–3] The exact prevalence is unknown, because symptoms 
are usually lacking. [4–6] Some children experience symp-
toms such as palpitations, but the PVC burden is usually not 
related to the severity of symptoms. In the pediatric popula-
tion frequent idiopathic PVCs and asymptomatic VTs were 
regarded as benign conditions with a good prognosis. [1, 6, 
7] However, recent data show that a high burden of PVCs 
(more than 20–30%) and asymptomatic VT can be asso-
ciated with left ventricular dysfunction in children [8–10]. 
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A causal relationship is suggested by the observations that 
left ventricular (LV) function usually recovers after effective 
treatment of ventricular arrhythmia [8, 9].
In general, frequent idiopathic PVCs and asymptomatic 
VTs in children do not require treatment. Guidelines rec-
ommend beta-blockers as first-line therapy of children with 
symptoms and of children in whom PVCs are thought to be 
causative of LV dysfunction [11, 12], with the exception 
of verapamil sensitive fascicular left ventricular VT. [13, 
14]. Catheter ablation is a good alternative in older children 
after failure of AAD therapy or in case of side effects of 
medication. [11, 12] Literature data on efficacy and safety 
of AAD therapy in children are scarce and limited to small 
series. [4, 7, 8] In adults, recent guidelines recommend the 
Class IC drug flecainide as first-line therapy for idiopathic 
outflow tract VTs and symptomatic patients with PVCs [11, 
15]. However, to date, there are no studies to support the use 
of flecainide as first-line therapy in children with frequent 
PVCs or asymptomatic VT. Therefore, the aim of this retro-
spective study is to compare the efficacy of anti-arrhythmic 
drugs for the treatment of frequent idiopathic PVCs and 
asymptomatic VT in children.
Methods
In this retrospective multi-center study, patients were 
enrolled from databases of four university hospitals and 
one large regional referral hospital. Children above 1 year 
and under 18 years of age, suffering from symptomatic or 
asymptomatic frequent PVCs, with or without asymptomatic 
(non-) sustained VT were studied. An official waiver of ethi-
cal approval was granted from the local ethical committee.
Symptomatic or asymptomatic patients with a PVC bur-
den of 5% [16] or more on 24-h Holter recording, with or 
without asymptomatic VT, and evaluated by consecutive 
Holter recordings were included. The decision to start AAD 
and the choice of AAD in the five different hospitals was 
based on institutional or physicians preference. Patients who 
received medication were included in four different groups 
based on the Vaughan Williams classification (Class I Na-
channel blocker, Class II beta-blocker, Class III K-channel 
blocker, Class IV Ca-channel blocker). Patients without 
anti-arrhythmic medication were included as control group. 
Patients with structural heart disease, history of cardiac 
surgery, myocarditis, and inherited arrhythmia syndromes 
(based on family history, genetics, ECG criteria, echocar-
diographic and/or MRI findings) were excluded. Further-
more, patients with polymorphic PVCs or VTs, fascicular 
left ventricular tachycardia or prior radiofrequency ablation 
procedures with multiple lesions were excluded. Children 
receiving anti-arrhythmic drug therapy less than one year 
of age were excluded because of the increased likelihood of 
spontaneous resolution of PVCs or VTs in this age group.
Baseline characteristics including gender, age, weight, 
and symptoms (e.g., palpitations, dizziness, fatigue, chest 
pain or syncope) were recorded. ECGs and 24- or 48-h 
Holter recordings were evaluated to document PVC burden, 
presence of (non-)sustained VT, dominant QRS morphology 
(axis and bundle branch block pattern), and coupling inter-
val (measured on ECG). Echocardiograms were reviewed 
to record the LV function and LV end-diastolic diameter 
(LVEDD), both were measured during sinus beats. LV dys-
function was defined as a shortening fraction of less than 
28% [17, 18]. LVEDD was indexed to body-surface area 
(BSA) and Z-scores were calculated. During follow-up, radi-
ofrequency ablation procedures were recorded.
A medication episode was defined as a timeframe in 
which the patient used only one type of anti-arrhythmic drug 
at a fixed dosage level. If the dosage was increased, only the 
medication episode with the highest dosage was included. 
Medication episodes with multiple medications at the same 
time were excluded. However, patients can be included in 
multiple groups if they received different AAD during sepa-
rate periods of time. When the physician’s records or corre-
spondence indicated poor adherence to medication, the epi-
sode was excluded. Any medication that was prescribed only 
for pill-in-the-pocket strategy (in which the patients only 
takes AAD at the moment of complaints) was not included.
The efficacy of the medication in each episode was based 
on Holter recordings, documented before and after the start 
of medication. The exact change in percentage of PVCs on 
Holter recording was calculated and analyzed as continuous 
data. Statistical tests were performed using SPSS version 
23.0 (IBM). The one-way ANOVA test was used to compare 
metric variables and the chi-square test for categorical vari-
ables. The changes in percentage of PVCs on Holter were 
tested using a gate-keeping procedure. At first an overall 
test was performed in a generalized linear mixed model, to 
determine if there was a difference between the five differ-
ent groups. This was followed by a pairwise comparison 
between the different groups P-values of 0.05 or lower were 
considered significant.
Results
Thirty-five Patients treated with AAD and 14 randomly 
selected patients without AAD (control group), evaluated 
by consecutive Holter recordings, were included. The 35 
patients treated with AAD had 46 medication episodes, 
with a maximum of 3 episodes per child. In total, flecainide 
was prescribed 10 times, beta-blockers 18 times, sotalol 7 
times, and verapamil 11 times. Children who received more 
than one type of anti-arrhythmic drugs during different 
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medication episodes are represented in more than one group. 
The 14 randomly selected untreated patients had 20 episodes 
with consecutive Holter recordings. The baseline character-
istics of the treated groups (before the start of medication) 
and control group were comparable regarding age at diag-
nosis, sex, weight, PVC burden, QRS morphology, coupling 
interval, and LV function (Table 1). The untreated group, as 
expected, had less symptoms, less VTs, and a lower LVEDD 
Z-score as compared to the treated groups. Symptoms in 
both the treated groups and the control group varied widely, 
consisting of palpitations, dizziness, fatigue, chest pain or 
syncope. The dosage of the medication prescribed was based 
on bodyweight and the way of administration depended on 
the patients age and available dosage form (i.e., multiple 
dosages per day or slow-release tablets). Therefore, the mean 
medication dose in mg per kg bodyweight per day is pre-
sented in Table 2.
The mean interval between Holter recordings was signifi-
cantly different between the five groups (p = 0,015), with the 
control group having the longest mean interval of 427 days 
(SD 310), the flecainide group 247 days (SD 253), the beta-
blocker group 139 days (SD 175), the sotalol group 261 days 
(SD 435), and the verapamil group 145 days (SD 160).
The mean follow-up time in our study was 3.8 years, 
with no statistically significant differences between the 
five groups (p = 0.924): 4.2 years for the control group (SD 
3.6), 3.4 years (SD 1.8) for children in the flecainide group, 
3.4 years (SD 3.2) in the beta-blocker group, 4.0 years (SD 
2.7) in the sotalol group, and 3.6 years (SD 1.6) in the vera-
pamil group.
Overall, the mean reduction in PVC burden on Holter 
recordings was − 4.4 percentage points (range − 46 to + 27 
percentage points) in the patients treated with AAD, com-
pared to − 4.2 percentage points (range − 21 to + 9 percent-
age points) in the control group. The reduction in PVC 
burden of the 5 groups is presented in Fig. 1. There was 
no relation between age and PVC burden in a linear regres-
sion model (p = 0.527). Patients in the flecainide group had 
a mean reduction of -13.8 percentage points (N = 10), in 
the beta-blockers group -1.7 percentage points (N = 18), in 
the sotalol group + 1.0 percentage points (N = 7) and in the 
verapamil group -3.9 percentage points (N = 11). The over-
all test from the generalized linear mixed model indicated 
Table 1  Baseline characteristics
Results are presented as N (%) and mean (SD). PVC burden = % of premature ventricular complexes per 24 h
VT = ventricular tachycardia, LBBB = left bundle branch block, RBBB = right bundel branch block, LV = left ventricle, SF = shortening fraction, 
LVEDD = left ventricular end-diastolic diameter
Controls
(N = 20)
Flecainide (N = 10) Beta-blocker (N = 18) Sotalol
(N = 7)
Verapamil (N = 11) p-values
Male 9 (45%) 5 (50%) 9 (50%) 3 (43%) 7 (64%) 0.884
Age at diagnosis (years) 11 (4.7) 9 (5.6) 9 (5.0) 12 (2.7) 11 (3.0) 0.316
Weight (kg) 44 (23) 37 (24) 35 (20) 49 (11) 45 (15) 0.461
Symptoms 6 (30%) 4 (40%) 7 (39%) 6 (86%) 9 (82%) 0.016
PVC burden mean (SD), 20 (10) 29 (14) 24 (14) 33 (8) 24 (14) 0.190
median (min–max) 19 (7–40) 25 (11–56) 25 (5–57) 35 (20–45) 25 (5–52)
(non-) sustained VT 2 (10%) 5 (50%) 8 (44%) 1 (17%) 6 (55%) 0.040
superior axis 3 (15%) 3 (30%) 2 (11%) 1 (14%) 0 (0%) 0.263
inferior axis 17 (85%) 6 (60%) 15 (83%) 6 (86%) 11 (100%)
LBBB pattern 16 (75%) 7 (70%) 14 (78%) 6 (86%) 10 (91%) 0.799
RBBB pattern 4 (25%) 3 (30%) 4 (22%) 1 (14%) 1 (9%)
Coupling interval (ms) 452 (56) 449 (113) 427 (98) 463 (71) 467 (71) 0.732
LV SF (%) 38 (5) 35 (6) 35 (4) 35 (8) 38 (4) 0.236
LV dysfunction 0 (0%) 2 (20%) 2 (11%) 1 (14%) 0 (0%) 0.238
LVEDD (mm) 44 (9) 46 (12) 42 (8) 49 (5) 45 (6) 0.458
LVEDD Z-score 0.79 (1.05) 2.13 (1.32) 1.20 (1.20) 1.72 (1.18) 0.92 (0.86) 0.032
Table 2  Anti-arrhythmic drug dosage
Mean anti-arrhythmic drug dosage and standard deviation in mg/kg 
bodyweight/day
Anti-arrhythmic drug Mean dose
Flecainide (N = 10) 3.6 (0.8)
Metoprolol (N = 10) 1.9 (0.9)
Propranolol (N = 5) 1.7 (0.7)
Atenolol (N = 3) 1.2 (0.7)
Sotalol (N = 7) 3.0 (1.4)
Verapamil (N = 11) 4.2 (1.1)
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significant differences in reduction of PVC burden between 
the five groups (four treatment groups plus control group) 
(p = 0,032). Looking at the pairwise comparisons of the 
treated patients versus the control patients, only the differ-
ence between the flecainide group and the control group 
was significant (p = 0,033).The four treatment groups were 
also tested in a generalized linear mixed model without the 
control group. In this overall test there was a significant dif-
ference between the four treatment groups (p = 0,023).
The groups were too small to be able to perform fur-
ther statistical analyses of subgroups with different dosages 
of medication. One patient with LV dysfunction had -46 
percentage points PVC reduction on flecainide therapy and 
full recovery of LV function. The PVC reduction was con-
firmed on multiple Holters, returned after discontinuation 
of flecainide and resolved again after restarting flecainide. 
Catheter ablation was not performed because during elec-
trophysiology study the PVC focus was located deep in the 
papillary muscle.
During follow-up, a catheter ablation procedure was 
performed in 14 patients with a mean age of 14 years (SD 
3.4 years). Indications for ablation were symptoms in com-
bination with failure of medication, and/or LV dysfunction. 
Of these procedures 11 were successful, with the focus of 
the PVCs in the right ventricular outflow tract (RVOT), at 
the right ventricular (RV) free wall or tricuspid annulus. 
Unsuccessful ablation sides were at the papillary muscle or 
LV summit.
Discussion
To our knowledge, this is the first study to compare the effi-
cacy of four types of anti-arrhythmic drugs in a group of 
children with frequent symptomatic or asymptomatic PVCs 
with or without asymptomatic VT to a control group. The 
main findings are: (1) the overall effect of anti-arrhythmic 
drugs (AAD) on frequent PVCs was very limited, with a 
mean change of the PVC burden on Holter recording of 
− 4.4 percentage points, compared to a control group with a 
change of − 4.2 percentage points; and (2) flecainide was the 
only AAD that significantly reduced the PVC burden (− 13.8 
percentage points) compared to other classes of AAD and 
the control group. Since flecainide appears to be the only 
effective anti-arrhythmic drug for the treatment of frequent 
PVCs, we argue that there is reason to use flecainide as first-
line AAD therapy if there is an indication to treat PVCs or 
non-sustained VT in children, which is contrary to current 
clinical practice.
In this study beta-blockers were the most frequently 
prescribed anti-arrhythmic drugs. This corresponds with a 
survey on AAD therapy preferences performed prior to this 
study, among 17 pediatric cardiologists from the participat-
ing centers. More than 70% of the respondents indicated 
that beta-blockers were their first-line medication, which is 
in accordance to international guidelines. [2, 12] However, 
evidence for these guidelines in children is scarce. Table 3 
summarizes the results of a review of the literature, which 
we performed by a PubMed search for AAD therapy in 
pediatric patients with premature ventricular complexes or 
ventricular tachycardia. Thus far, only small retrospective 
series are published, none of the studies is large enough to 
reach statistical significance. As expected, beta-blockers 
are the most commonly used AAD, but treatment with all 
classes of AAD is described. Most series only report patients 
with VT, of which the study by Pfammatter et al. in 1999 
was the largest. They reported a retrospective series of 73 
children with VT, in which beta-blockers and sotalol were 
administered the most, with a response rate of 35% and 62%, 
respectively. Both class Ic drugs propafenone and flecainide 
had a response rate of 65%. Two other smaller studies also 
included patients with PVCs. A series on drug efficacy in 
28 children with > 5% PVCs was published by Kakavand 
et al. (2010) and observed that only atenolol and flecainide 
appeared to be effective [8]. Heusch et al. (1994) found that 
propafenone (Class 1C) was effective in two out of five 
Fig. 1  Mean change in PVC burden. Central Illustration: Mean 
change in PVC burden on Holter in percentage points: mean (+), 




Table 3  Review of available evidence of efficacy of AAD in the pediatric age group
Year of publication
First author
Age Type of ventricu-
lar arrhythmia
AAD used # patients using 
AAD










92 fascicular 73 (80) Conversion to sinus 
rhythm or preven-








(0 to 17.9 yrs)
VT Procainamide 2 0 (0) Improvement expe-
rienced by patients 
on the specified 
medication
Mexiletine 4 3 (75)
Propafenone 8 4 (50)
Flecainide 1 1 (100)
Beta-blockers 15 11 (73)
Amiodarone 6 6 (100)








VT Procainamide 4 (2 incl Proprano-
lol)
The time to ven-
tricular tachycardia 
resolutionLidocaine 13









PVC > 5% Mexiletine 1 0 (0) Not described
Case presented of 
flecainide effect 
with decrease 
in PVC burden 
of 60% to < 1%, 
and recurrence of 
PVCs after out-
growing dosage
Flecainide 1 1 (100)
Beta-blockers 13 Atenolol effective
Class IV 1 0 (0)




(5 to 15 yrs)
VT Mexiletine 6 (4 incl BB) The decrease in 
VT episodes of 
more than 90% on 
Holter monitoring
Beta-blockers 13
Verapamil 7 (3 incl BB)




(0.1 to 15.1 yrs)





Flecainide 6 4 (65)
Beta-blocker 23 8 (35)
Amiodarone 18 16 (89)
Sotalol 21 13 (62)
Verapamil 8 7 (88)




(1 day to 4.8 yrs)







(1 mnth to 18 yrs)
VT Beta-blockers 28 16 (57) The complete 
absence of VT 
in at least 2 con-
secutive Holter, 
ECG or treadmill 
exercise tests
Class IV 14 11 (79)
Propafenone 6 4 (67)
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children with PVCs (4 patients) or VT (1 patient), and a 
structurally normal heart [19].
In the adult population with frequent PVCs there is more 
evidence for the efficacy of anti-arrhythmic drugs. In an 
open-label cross-over trial in 84 patients with idiopathic 
PVCs, Stec et al. (2012) showed that 42% responded to 
propafenone, 15% to verapamil, and 10% to metoprolol 
(p < 0.01). [20] Their results of low response rates match 
the results of this study; the high response to propafenone 
supports our findings that flecainide may be more effective 
than other classes of anti-arrhythmic drugs. [20] Gill et al. 
(1992) performed a cross-over study in 23 patients with right 
sided VT, who were serially prescribed verapamil, sotalol, 
and flecainide. [21] All three drugs caused a partial response 
documented on Holters, and authors concluded that sotalol 
was most effective, although no significant differences were 
found. [21] Krittayaphong et al. (2002) report in a placebo-
controlled trial in 52 patients that atenolol significantly 
decreased symptoms and PVC count, from 24.082 to 16.153 
per 24 h. [22] According to their criteria, the response rate 
was 24% in the atenolol group. Although placebo did not 
reduce the PVC count, it significantly decreased symptoms, 
demonstrating a strong placebo effect. However, a recent 
study by Hamon et al. (2019) describes that in a subgroup of 
patients the burden of PVCs can even be increased by beta-
blockers, since usually PVCs are reduced at higher heart 
rates [23]. This might explain why the increase of PVCs 
in our study group is highest in the beta-blocker group. An 
extensive meta-analysis published in 1990, including 95 
studies and 2989 patients, reported that class IC drugs and 
amiodarone were significantly more effective in treating 
ventricular ectopy [24]. However, 82% of the patients had a 
history of cardiovascular disease and, therefore, are difficult 
to compare to the population with idiopathic PVCs.
This retrospective study has a number of limitations. 
Although it is the largest series of children reported with 
symptomatic or asymptomatic frequent PVCs with or with-
out asymptomatic VT, the sample size remains small. The 
control group is relatively small, because only children with 
consecutive Holter recordings could be included, to be able 
to assess the change in PVC burden. The study design did 
allow for multiple medication episodes per patient. The 
mean dosage of the AAD used in this retrospective study 
was relatively low; however, the mean dosage of all groups 
of AAD drugs were in the lower range and still flecainide 
shows a better result.
In addition, the self-limiting nature of this condition may 
have influenced the results. But there is no reason to assume 
that this has occurred more often in one of the groups with 
medication, than in the control group. The control group 
even had the longest interval between Holter recordings, fur-
thermore we found no relation between age and PVC burden.
A randomized controlled trial would prevent many of 
these factors from interfering. Therefore, we are currently 
performing an open-label cross-over trial, intended to com-
pare efficacy of flecainide to metoprolol in a population of 
children with more than 15% PVCs.
Conclusions
In children with frequent symptomatic or asymptomatic 
PVCs with or without asymptomatic VT, the efficacy of 
anti-arrhythmic drug therapy is very limited. Only flecainide 
appears to have a statistically significant effect on reducing 
ventricular ectopy.
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